On the public citation graph

Key cost drivers of pharmaceutical clinical trials in the United States

https://doi.org/10.1177/1740774515625964
0 signed · 410 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1016/j.healthpol.2010.12.002openalex-snapshot
The cost of drug development: A systematic review
inferredcites →https://doi.org/10.1016/s0167-6296(02)00126-1openalex-snapshot
The price of innovation: new estimates of drug development costs
inferredcites →https://doi.org/10.1038/clpt.2011.341openalex-snapshot
Impediments to Clinical Research in the United States
inferredcites →https://doi.org/10.1056/nejmsb1300760openalex-snapshot
Randomized Clinical Trials — Removing Unnecessary Obstacles
inferredcites →https://doi.org/10.1097/mjt.0b013e31816b9027openalex-snapshot
Assessing the Impact of Protocol Design Changes on Clinical Trial Performance
inferredcites →https://doi.org/10.1177/009286151004400412openalex-snapshot
PhRMA BioResearch Monitoring Committee Perspective on Acceptable Approaches for Clinical Trial Monitoring
inferredcites →https://doi.org/10.1177/009286151004400611openalex-snapshot
Risk-Based Source Data Verification Approaches: Pros and Cons
inferredcites →https://doi.org/10.1177/1740774507087551openalex-snapshot
Sensible approaches for reducing clinical trial costs
inferredcites →https://doi.org/10.1177/2168479013494386openalex-snapshot
New Governance Mechanisms to Optimize Protocol Design
inferredcites →https://doi.org/10.1200/jco.2003.08.156openalex-snapshot
The Costs of Conducting Clinical Research
inferredcites →https://doi.org/10.1201/b16842openalex-snapshot
Basic Statistics and Pharmaceutical Statistical Applications
inferredcites →https://doi.org/10.1377/hlthaff.25.2.420openalex-snapshot
Estimating The Cost Of New Drug Development: Is It Really $802 Million?
inferredcites →https://doi.org/10.1503/cmaj.082041openalex-snapshot
Rapidly rising clinical trial costs worry researchers
inferredcites →https://doi.org/10.1586/17512433.2013.841539openalex-snapshot
Drug development study designs have reached the danger zone
inferredcites →https://doi.org/10.17226/9623openalex-snapshot
Assuring Data Quality and Validity in Clinical Trials for Regulatory Decision Making
inferredcites →https://doi.org/10.31478/201205eopenalex-snapshot
Transforming the Economics of Clinical Trials
inferredcites →https://doi.org/10.3945/an.114.007211openalex-snapshot
Centers for Disease Control and Prevention. State Indicator Report on Physical Activity, 2014. Atlanta, GA: U.S. Department of Health and Human Services; 2014

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.3479439openalex-extracted
Do Venture Capitalists Stifle Competition?
inferred← citeshttps://doi.org/10.2139/ssrn.3713924openalex-extracted
Adaptive Design of Clinical Trials: A Sequential Learning Approach
inferred← citeshttps://doi.org/10.2139/ssrn.3883041openalex-extracted
Mapping the Cancer Genome and R&D Decisions in the Pharmaceutical Industry
inferred← citeshttps://doi.org/10.2139/ssrn.4300678openalex-extracted
Valuing Pharmaceutical Drug Innovations
inferred← citeshttps://doi.org/10.2139/ssrn.4558321openalex-extracted
Excess Commitment in R&D
inferred← citeshttps://doi.org/10.2139/ssrn.4928902openalex-extracted
Representation in Product Development: Evidence from Insurance and Clinical Trials
inferred← citeshttps://doi.org/10.1001/jama.2025.4728openalex-snapshot
NIH Funding Has Stagnated Since 2003
inferred← citeshttps://doi.org/10.1001/jamainternmed.2018.3930openalex-snapshot
Clinical Trials—We Get What We Pay For
inferred← citeshttps://doi.org/10.1001/jamainternmed.2018.3931openalex-snapshot
Estimated Costs of Pivotal Trials for Novel Therapeutic Agents Approved by the US Food and Drug Administration, 2015-2016
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2020.14682openalex-snapshot
Assessment of Trends in the Design, Accrual, and Completion of Trials Registered in ClinicalTrials.gov by Sponsor Type, 2000-2019
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2021.11847openalex-snapshot
Practices and Attitudes of Swiss Stakeholders Regarding Investigator-Initiated Clinical Trial Funding Acquisition and Cost Management
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.31609openalex-snapshot
Estimated Cost of Developing a Therapeutic Complex Medical Device in the US
inferred← citeshttps://doi.org/10.1001/jamaoncol.2018.1739openalex-snapshot
New Business Models to Accelerate Innovation in Pediatric Oncology Therapeutics
inferred← citeshttps://doi.org/10.1002/9781119913276.ch8openalex-snapshot
Phase 2
inferred← citeshttps://doi.org/10.1002/9781394287383.ch3openalex-snapshot
Data Science and AI for Transforming R&D
inferred← citeshttps://doi.org/10.1002/adhm.202203172openalex-snapshot
Recent Advances in Organ‐on‐Chips Integrated with Bioprinting Technologies for Drug Screening
inferred← citeshttps://doi.org/10.1002/adtp.202400124openalex-snapshot
Material Trends and Clinical Costings in Systematically Identified CDER‐Approved Nanomedicines
inferred← citeshttps://doi.org/10.1002/bit.27496openalex-snapshot
Media supplementation for targeted manipulation of monoclonal antibody galactosylation and fucosylation
inferred← citeshttps://doi.org/10.1002/bit.28221openalex-snapshot
All‐in‐one microfluidic design to integrate vascularized tumor spheroid into high‐throughput platform
inferred← citeshttps://doi.org/10.1002/cbdv.202502495openalex-snapshot
Insect‐derived Compounds as Novel Source for Drug Discovery: A Systematic Review and Critical In Silico Analysis
inferred← citeshttps://doi.org/10.1002/cmdc.202500747openalex-snapshot
Enhancing Drug Repurposing with Consensus Docking: Discovery of Novel Discoidin Domain Receptor 1 Inhibitors
inferred← citeshttps://doi.org/10.1002/cncr.35528openalex-snapshot
Feasibility of structuring electronic health record data to facilitate real‐world data research: ICAREdata methods applied to multicenter cancer clinical trials
inferred← citeshttps://doi.org/10.1002/cpt.1658openalex-snapshot
Examining the Use of Real‐World Evidence in the Regulatory Process
inferred← citeshttps://doi.org/10.1002/cpt.691openalex-snapshot
Occlusion in the Flow of New Drugs for Cardiovascular Disease
inferred← citeshttps://doi.org/10.1002/ddr.22188openalex-snapshot
Comparisons of successful and failed Phase III trials of drugs and biologicals tested for mitigation of oral mucositis in patients being treated with radiotherapy with or without concomitant chemotherapy for cancers of the head and neck
inferred← citeshttps://doi.org/10.1002/jcph.70077openalex-snapshot
Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects
inferred← citeshttps://doi.org/10.1002/ksa.12657openalex-snapshot
Beyond traditional orthopaedic data analysis: AI, multimodal models and continuous monitoring
inferred← citeshttps://doi.org/10.1002/lrh2.10327openalex-snapshot
Evolving a national clinical trials learning health system
inferred← citeshttps://doi.org/10.1002/masy.202300022openalex-snapshot
Computational/In‐Silico Methods: An Influential Approach for Drug Designing and Development
inferred← citeshttps://doi.org/10.1002/onco.13759openalex-snapshot
Publication Bias in Gastrointestinal Oncology Trials Performed over the Past Decade
inferred← citeshttps://doi.org/10.1002/prp2.355openalex-snapshot
Higher patient satisfaction with antidepressants correlates with earlier drug release dates across online user‐generated medical databases
inferred← citeshttps://doi.org/10.1002/pst.2203openalex-snapshot
Bayesian adaptive randomization design incorporating propensity score‐matched historical controls
inferred← citeshttps://doi.org/10.1002/pst.2442openalex-snapshot
Balance Index to Determine the Follow‐Up Duration of Oncology Trials
inferred← citeshttps://doi.org/10.1002/sim.10061openalex-snapshot
A two‐stage group‐sequential design for delayed treatment responses with the possibility of trial restart
inferred← citeshttps://doi.org/10.1002/ueg2.12455openalex-snapshot
Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease
inferred← citeshttps://doi.org/10.1007/978-1-0716-0282-9_1openalex-snapshot
Current and Future Challenges in Modern Drug Discovery
inferred← citeshttps://doi.org/10.1007/978-1-0716-1358-0_1openalex-snapshot
Worldwide Clinical Demand for Antibiotics: Is It a Real Countdown?
inferred← citeshttps://doi.org/10.1007/978-3-030-47682-3_1openalex-snapshot
The Development of a Drug: A Pharmaceutical Drug Development Perspective
inferred← citeshttps://doi.org/10.1007/978-3-030-75055-8_7openalex-snapshot
Novel Research Designs
inferred← citeshttps://doi.org/10.1007/978-3-030-78338-9_3openalex-snapshot
Immunotherapy: From Discovery to Bedside
inferred← citeshttps://doi.org/10.1007/978-3-030-89906-6_41openalex-snapshot
Exploring the Freedoms in Data Mining: Why the Trustworthiness and Integrity of the Findings are the Casualties, and How to Resolve These?
inferred← citeshttps://doi.org/10.1007/978-3-031-62877-1_5openalex-snapshot
Goals and Metrics of Success
inferred← citeshttps://doi.org/10.1007/978-3-032-36710-5_2openalex-snapshot
Silent Responsibility Voids: Evidence for Process Twins in Clinical Trials
inferred← citeshttps://doi.org/10.1007/978-981-13-6065-7_8openalex-snapshot
Billions of Dollars Worth of Experiments: Calibrating Clinical Trial Investments
inferred← citeshttps://doi.org/10.1007/s00134-024-07665-4openalex-snapshot
Causal inference can lead us to modifiable mechanisms and informative archetypes in sepsis
inferred← citeshttps://doi.org/10.1007/s00210-020-01998-9openalex-snapshot
Repurposing mesalazine against cardiac fibrosis in vitro
inferred← citeshttps://doi.org/10.1007/s00210-021-02135-wopenalex-snapshot
Systemic mesalazine treatment prevents spontaneous skin fibrosis in PLK2-deficient mice
inferred← citeshttps://doi.org/10.1007/s00210-025-04289-3openalex-snapshot
Innovative horizons: harnessing drug repositioning for targeted therapeutics in colorectal cancer
inferred← citeshttps://doi.org/10.1007/s00395-025-01141-wopenalex-snapshot
The CNP analogue vosoritide mediates PDE2-sensitive anti-arrhythmogenic effects in mouse hearts with STZ-induced type 1 diabetes
inferred← citeshttps://doi.org/10.1007/s10479-023-05382-7openalex-snapshot
Improving the performance of supply chains in clinical trials with delays: an optimization approach to determining the number of recruitment sites
inferred← citeshttps://doi.org/10.1007/s10847-025-01283-3openalex-snapshot
A novel multicellular organ-on-a-chip platform for high-throughput screening of urothelial responses
inferred← citeshttps://doi.org/10.1007/s11427-022-2239-yopenalex-snapshot
PanGu Drug Model: learn a molecule like a human
inferred← citeshttps://doi.org/10.1007/s11912-020-00904-zopenalex-snapshot
Developing Real-world Evidence-Ready Datasets: Time for Clinician Engagement
inferred← citeshttps://doi.org/10.1007/s12170-021-00673-9openalex-snapshot
Feasibility of Incorporating Voice Technology and Virtual Assistants in Cardiovascular Care and Clinical Trials
inferred← citeshttps://doi.org/10.1007/s12247-025-09975-6openalex-snapshot
Identification and Predictive Analysis of Revenue Determinants in the Pharma Industry: A Longitudinal Analysis of Financial, Regulatory and Pipeline Data
inferred← citeshttps://doi.org/10.1007/s12312-018-0476-2openalex-snapshot
Forschungsförderung/Studienfinanzierung für eine ökonomisch vertretbare onkologische Therapie
inferred← citeshttps://doi.org/10.1007/s13721-025-00502-8openalex-snapshot
A survey on computational methods used for drug repositioning
inferred← citeshttps://doi.org/10.1007/s40273-020-00944-0openalex-snapshot
Incorporating Pharmacometrics into Pharmacoeconomic Models: Applications from Drug Development
inferred← citeshttps://doi.org/10.1007/s40273-023-01248-9openalex-snapshot
HTA Barriers for Conditional Approval Drugs
inferred← citeshttps://doi.org/10.1007/s40290-025-00558-xopenalex-snapshot
Cost and Duration of Clinical Trials in Drug Development by Japanese Pharmaceutical Companies
inferred← citeshttps://doi.org/10.1007/s40615-022-01367-7openalex-snapshot
The Role of Transportation in the Enrollment of Elderly African Americans into Exercise and Memory Study: GEMS Study
inferred← citeshttps://doi.org/10.1007/s41649-019-00085-3openalex-snapshot
Hypocrisy Around Medical Patient Data: Issues of Access for Biomedical Research, Data Quality, Usefulness for the Purpose and Omics Data as Game Changer
inferred← citeshttps://doi.org/10.1007/s42399-020-00549-wopenalex-snapshot
Cancerona: Challenges of Cancer Management in Times of COVID-19 Pandemic
inferred← citeshttps://doi.org/10.1007/s43441-023-00509-1openalex-snapshot
Factors Affecting Success of New Drug Clinical Trials
inferred← citeshttps://doi.org/10.1016/b978-0-12-804725-5.00005-7openalex-snapshot
Addressing Reproducibility: Peer Review, Impact Factors, Checklists, Guidelines, and Reproducibility Initiatives
inferred← citeshttps://doi.org/10.1016/b978-0-12-816221-7.00005-7openalex-snapshot
Advanced microtechnologies for high-throughput screening
inferred← citeshttps://doi.org/10.1016/b978-0-12-816920-9.15009-6openalex-snapshot
Developing and testing new therapies: clinical trials
inferred← citeshttps://doi.org/10.1016/b978-0-12-819837-7.00003-0openalex-snapshot
Medications registration and marketing: safety-related issues
inferred← citeshttps://doi.org/10.1016/b978-0-12-819967-1.00036-0openalex-snapshot
Challenges in clinical breath research development
inferred← citeshttps://doi.org/10.1016/b978-0-323-90300-4.00090-2openalex-snapshot
Drug testing: translating a novel immunotherapeutic from bench to bedside
inferred← citeshttps://doi.org/10.1016/b978-0-323-91819-0.00002-6openalex-snapshot
Artificial intelligence: A regulatory perspective
inferred← citeshttps://doi.org/10.1016/b978-0-443-13750-1.00023-9openalex-snapshot
Research funding
inferred← citeshttps://doi.org/10.1016/b978-0-443-15280-1.00011-xopenalex-snapshot
Principles of computational drug designing and drug repurposing—An algorithmic approach
inferred← citeshttps://doi.org/10.1016/b978-0-443-18748-3.00010-xopenalex-snapshot
Biopharmaceutical product development strategies
inferred← citeshttps://doi.org/10.1016/b978-0-443-23848-2.00001-2openalex-snapshot
The modern-day drug discovery
inferred← citeshttps://doi.org/10.1016/b978-0-443-33304-0.00011-3openalex-snapshot
Functionalized drug delivery systems: regulatory considerations
inferred← citeshttps://doi.org/10.1016/bs.irrdd.2022.05.002openalex-snapshot
Remotely monitoring treatment outcomes in patients with neurogenetic syndromes: A family-centered perspective
inferred← citeshttps://doi.org/10.1016/j.addr.2020.08.008openalex-snapshot
Recent trends in protein and peptide-based biomaterials for advanced drug delivery
inferred← citeshttps://doi.org/10.1016/j.addr.2021.113971openalex-snapshot
Local delivery strategies to restore immune homeostasis in the context of inflammation
inferred← citeshttps://doi.org/10.1016/j.aichem.2023.100011openalex-snapshot
Application of artificial intelligence and machine learning in early detection of adverse drug reactions (ADRs) and drug-induced toxicity
inferred← citeshttps://doi.org/10.1016/j.apmr.2021.04.009openalex-snapshot
The Time Is Now: A FASTER Approach to Generate Research Evidence for Technology-Based Interventions in the Field of Disability and Rehabilitation
inferred← citeshttps://doi.org/10.1016/j.bcp.2025.117412openalex-snapshot
Bosutinib alleviates peritoneal fibrosis by regulating mesothelial-to-mesenchymal transition through inhibition of the PI3K/AKT pathway
inferred← citeshttps://doi.org/10.1016/j.biopha.2025.118704openalex-snapshot
EPICYCLE: A confirmatory preclinical study of the anti-rhabdomyosarcoma efficacy of BET bromodomain and cyclin-dependent kinase 9 inhibitors
inferred← citeshttps://doi.org/10.1016/j.burns.2017.11.001openalex-snapshot
Burn clinical trials: A systematic review of registration and publications
inferred← citeshttps://doi.org/10.1016/j.cct.2019.105874openalex-snapshot
Sequential monitoring of covariate adaptive randomized clinical trials with sample size re-estimation
inferred← citeshttps://doi.org/10.1016/j.cct.2021.106368openalex-snapshot
Risk-based centralized data monitoring of clinical trials at the time of COVID-19 pandemic
inferred← citeshttps://doi.org/10.1016/j.cct.2021.106401openalex-snapshot
Estimating the financial costs associated with a phase III, multi-site exercise intervention trial: Investigating Gains in Neurocognition in an Intervention Trial of Exercise (IGNITE)
inferred← citeshttps://doi.org/10.1016/j.cct.2021.106646openalex-snapshot
Exploring the pragmatic-explanatory spectrum across cardiovascular clinical trials
inferred← citeshttps://doi.org/10.1016/j.cct.2022.106715openalex-snapshot
Non-oncology clinical trial engagement in a nationally representative sample: Identification of motivators and barriers
inferred← citeshttps://doi.org/10.1016/j.cct.2023.107144openalex-snapshot
Assessing clinical site readiness for electronic health record (EHR)-to-electronic data capture (EDC) automated data collection
inferred← citeshttps://doi.org/10.1016/j.clgc.2020.08.003openalex-snapshot
Causal Diagram Techniques for Urologic Oncology Research
inferred← citeshttps://doi.org/10.1016/j.clinthera.2017.03.018openalex-snapshot
Incorporating Site-less Clinical Trials Into Drug Development: A Framework for Action
inferred← citeshttps://doi.org/10.1016/j.clinthera.2026.08.012openalex-snapshot
Issues in Monitoring Oncology Trials
inferred← citeshttps://doi.org/10.1016/j.compchemeng.2017.05.027openalex-snapshot
Building pharmacokinetic compartmental models using a superstructure approach
inferred← citeshttps://doi.org/10.1016/j.conctc.2018.06.008openalex-snapshot
Building clinical trials around patients: Evaluation and comparison of decentralized and conventional site models in patients with low back pain
inferred← citeshttps://doi.org/10.1016/j.conctc.2021.100718openalex-snapshot
Sociodemographic diversity in cancer clinical trials: New findings on the effect of race and ethnicity
inferred← citeshttps://doi.org/10.1016/j.conctc.2024.101257openalex-snapshot
Evaluating registry-based trial economics: Results from the STRESS clinical trial
inferred← citeshttps://doi.org/10.1016/j.conctc.2024.101391openalex-snapshot
Defining methods to improve eSource site start-up practices
inferred← citeshttps://doi.org/10.1016/j.drudis.2019.03.025openalex-snapshot
Microfluidic bioprinting for organ-on-a-chip models
inferred← citeshttps://doi.org/10.1016/j.drudis.2019.06.005openalex-snapshot
Data science tools and applications on the way to Pharma 4.0
inferred← citeshttps://doi.org/10.1016/j.drudis.2019.10.014openalex-snapshot
A drug-likeness toolbox facilitates ADMET study in drug discovery
inferred← citeshttps://doi.org/10.1016/j.drudis.2021.09.012openalex-snapshot
Combining repurposed drugs to treat colorectal cancer
inferred← citeshttps://doi.org/10.1016/j.ejpb.2020.05.005openalex-snapshot
Preclinical challenges for developing long acting intravitreal medicines
inferred← citeshttps://doi.org/10.1016/j.esmoop.2023.101633openalex-snapshot
Unlocking digitally enabled research in oncology: the time is now
inferred← citeshttps://doi.org/10.1016/j.etdah.2022.100045openalex-snapshot
Financing pharmaceuticals and medical devices for pain treatment and opioid use disorder
inferred← citeshttps://doi.org/10.1016/j.heliyon.2024.e39699openalex-snapshot
Comprehensive review of opportunities and challenges of ethnomedicinal plants for managing type 2 diabetes
inferred← citeshttps://doi.org/10.1016/j.ijcard.2025.133901openalex-snapshot
Predictors of discontinuation and non-publication of heart failure clinical trials: A cross-sectional analysis of ClinicalTrials.gov data
inferred← citeshttps://doi.org/10.1016/j.ijmedinf.2020.104095openalex-snapshot
Pilot trial of semi-automated medical note writing using lexeme hypotheses
inferred← citeshttps://doi.org/10.1016/j.ijmedinf.2025.106141openalex-snapshot
Artificial intelligence in clinical trials: A comprehensive review of opportunities, challenges, and future directions
inferred← citeshttps://doi.org/10.1016/j.ijporl.2020.110108openalex-snapshot
A survey of adult preferences regarding recruitment for pediatric research
inferred← citeshttps://doi.org/10.1016/j.inpm.2025.100709openalex-snapshot
Feasibility of a mobile application to track longitudinal pain outcomes after epidural joint injections
inferred← citeshttps://doi.org/10.1016/j.jacbts.2017.09.002openalex-snapshot
Overcoming the Declining Trends in Innovation and Investment in Cardiovascular Therapeutics
inferred← citeshttps://doi.org/10.1016/j.jaccas.2023.102048openalex-snapshot
Cardiovascular Imaging in Clinical Trial Design
inferred← citeshttps://doi.org/10.1016/j.jacl.2026.03.018openalex-snapshot
Identifying severe hypercholesterolemia in participants of ASCVD trials: Implications for trial conduct and opportunistic screening
inferred← citeshttps://doi.org/10.1016/j.jbc.2022.102028openalex-snapshot
Giardia intestinalis thymidine kinase is a high-affinity enzyme crucial for DNA synthesis and an exploitable target for drug discovery
inferred← citeshttps://doi.org/10.1016/j.jcjo.2025.05.022openalex-snapshot
Impact of 11 years of glaucoma research funding: Glaucoma Research Society of Canada (2010–2020)
inferred← citeshttps://doi.org/10.1016/j.jclinepi.2017.12.018openalex-snapshot
Systematic review on costs and resource use of randomized clinical trials shows a lack of transparent and comprehensive data
inferred← citeshttps://doi.org/10.1016/j.jclinepi.2017.12.022openalex-snapshot
Retrospective assessment of resource use and costs in two investigator-initiated randomized trials exemplified a comprehensive cost item list
inferred← citeshttps://doi.org/10.1016/j.jclinepi.2020.04.021openalex-snapshot
COllaborative open platform E-cohorts for research acceleration in trials and epidemiology
inferred← citeshttps://doi.org/10.1016/j.jclinepi.2020.09.035openalex-snapshot
Prerandomization run-in periods in randomized controlled trials of chronic diseases: a methodological study
inferred← citeshttps://doi.org/10.1016/j.jclinepi.2023.08.005openalex-snapshot
Metaresearch study highlights the gender gap in randomized controlled trials in dentistry
inferred← citeshttps://doi.org/10.1016/j.jclinepi.2024.111536openalex-snapshot
Resource use and costs of investigator-sponsored randomized clinical trials in Switzerland, Germany, and the United Kingdom: a metaresearch study
inferred← citeshttps://doi.org/10.1016/j.jclinepi.2025.111718openalex-snapshot
Endpoint assessment via routinely collected data generates estimates comparable to randomized controlled trial data: analysis of a cluster-randomized trial on fall injury prevention
inferred← citeshttps://doi.org/10.1016/j.jcmg.2017.01.003openalex-snapshot
Imaging Registries and Single-Center Series
inferred← citeshttps://doi.org/10.1016/j.jcpo.2021.100305openalex-snapshot
Accelerating cancer clinical trial recruitment through a financial reimbursement program integrated with patient navigation: an interrupted time series analysis
inferred← citeshttps://doi.org/10.1016/j.jfineco.2022.12.004openalex-snapshot
Common ownership and innovation efficiency
inferred← citeshttps://doi.org/10.1016/j.jhealeco.2023.102795openalex-snapshot
An optimal mechanism to fund the development of vaccines against emerging epidemics
inferred← citeshttps://doi.org/10.1016/j.joca.2017.11.011openalex-snapshot
Spontaneous painful disease in companion animals can facilitate the development of chronic pain therapies for humans
inferred← citeshttps://doi.org/10.1016/j.jpain.2019.12.003openalex-snapshot
Improving Study Conduct and Data Quality in Clinical Trials of Chronic Pain Treatments: IMMPACT Recommendations
inferred← citeshttps://doi.org/10.1016/j.jpba.2018.07.011openalex-snapshot
Microfluidics contribution to pharmaceutical sciences: From drug discovery to post marketing product management
inferred← citeshttps://doi.org/10.1016/j.jsps.2021.04.004openalex-snapshot
Anthelmintics for drug repurposing: Opportunities and challenges
inferred← citeshttps://doi.org/10.1016/j.knosys.2019.104977openalex-snapshot
Multi-target QSAR modelling of chemo-genomic data analysis based on Extreme Learning Machine
inferred← citeshttps://doi.org/10.1016/j.mtbio.2023.100553openalex-snapshot
Application of microfluidic chips in the simulation of the urinary system microenvironment
inferred← citeshttps://doi.org/10.1016/j.mtchem.2024.102111openalex-snapshot
GelMA hydrogel: A game-changer in 3D tumor modeling
inferred← citeshttps://doi.org/10.1016/j.patter.2023.100689openalex-snapshot
Deep learning-based risk prediction for interventional clinical trials based on protocol design: A retrospective study
inferred← citeshttps://doi.org/10.1016/j.phrs.2017.04.027openalex-snapshot
Age and sex in drug development and testing for adults
inferred← citeshttps://doi.org/10.1016/j.ppedcard.2020.101254openalex-snapshot
Disruption of healthcare: Will the COVID pandemic worsen non-COVID outcomes and disease outbreaks?
inferred← citeshttps://doi.org/10.1016/j.reth.2019.04.004openalex-snapshot
Insights into the biology of fibrodysplasia ossificans progressiva using patient-derived induced pluripotent stem cells
inferred← citeshttps://doi.org/10.1016/j.sajb.2023.09.009openalex-snapshot
Therapeutic potential of the genus Zanthoxylum phytochemicals: A theoretical ADME/Tox analysis
inferred← citeshttps://doi.org/10.1016/j.sapharm.2019.06.010openalex-snapshot
Should the United States government regulate prescription prices? A critical review
inferred← citeshttps://doi.org/10.1016/j.socscimed.2022.114953openalex-snapshot
Inequities in cancer drug development in terms of unmet medical need
inferred← citeshttps://doi.org/10.1016/j.tibtech.2022.08.007openalex-snapshot
Artificial intelligence and machine learning applications in biopharmaceutical manufacturing
inferred← citeshttps://doi.org/10.1016/j.tiv.2023.105740openalex-snapshot
Pyruvate dehydrogenase is a potential mitochondrial off-target for gentamicin based on in silico predictions and in vitro inhibition studies
inferred← citeshttps://doi.org/10.1016/s0140-6736(23)02199-2openalex-snapshot
The need for pragmatic, affordable, and practice-changing real-life clinical trials in oncology
inferred← citeshttps://doi.org/10.1016/s1470-2045(20)30730-0openalex-snapshot
Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis
inferred← citeshttps://doi.org/10.1017/9781009391733.006openalex-snapshot
Rethinking Research
inferred← citeshttps://doi.org/10.1017/9781009391733.011openalex-snapshot
Understanding and Restraining Study Costs
inferred← citeshttps://doi.org/10.1017/9781009746274.015openalex-snapshot
Paying for medicines
inferred← citeshttps://doi.org/10.1017/9781108687676.007openalex-snapshot
Notes
inferred← citeshttps://doi.org/10.1017/cts.2023.699openalex-snapshot
The impact of lowering the study design significance threshold to 0.005 on sample size in randomized cancer clinical trials
inferred← citeshttps://doi.org/10.1017/s0266462319003532openalex-snapshot
Closing the cycle of innovation in healthcare in Europe
inferred← citeshttps://doi.org/10.1017/s1047951120001018openalex-snapshot
Registry-based trials: a potential model for cost savings?
inferred← citeshttps://doi.org/10.1021/acs.jcim.3c01317openalex-snapshot
Introducing the Automated Ligand Searcher
inferred← citeshttps://doi.org/10.1021/acsbiomaterials.3c00089openalex-snapshot
3D Inkjet-Bioprinted Lung-on-a-Chip
inferred← citeshttps://doi.org/10.1038/540s63aopenalex-snapshot
Regulation: Rewriting the regenerative rulebook
inferred← citeshttps://doi.org/10.1038/bioe.2017.1openalex-snapshot
So you want to be a student entrepreneur?
inferred← citeshttps://doi.org/10.1038/nbt.3778openalex-snapshot
So you want to be a student entrepreneur?
inferred← citeshttps://doi.org/10.1038/nrcardio.2017.60openalex-snapshot
Efficient design of clinical trials and epidemiological research: is it possible?
inferred← citeshttps://doi.org/10.1038/s41375-021-01164-xopenalex-snapshot
Two decades of targeted therapies in acute myeloid leukemia
inferred← citeshttps://doi.org/10.1038/s41378-021-00277-8openalex-snapshot
Tumor-on-a-chip: from bioinspired design to biomedical application
inferred← citeshttps://doi.org/10.1038/s41409-025-02694-zopenalex-snapshot
Real-world graft utilization after CTN-1101: a registry-based analysis of haploidentical graft versus umbilical cord blood trends
inferred← citeshttps://doi.org/10.1038/s41571-018-0030-2openalex-snapshot
Low-value approvals and high prices might incentivize ineffective drug development
inferred← citeshttps://doi.org/10.1038/s41591-021-01519-yopenalex-snapshot
Individualized therapy trials: navigating patient care, research goals and ethics
inferred← citeshttps://doi.org/10.1038/s41591-022-01981-2openalex-snapshot
Multimodal biomedical AI
inferred← citeshttps://doi.org/10.1038/s41597-025-05343-8openalex-snapshot
PubMed knowledge graph 2.0: Connecting papers, patents, and clinical trials in biomedical science
inferred← citeshttps://doi.org/10.1038/s41598-018-25954-zopenalex-snapshot
Long term extension of a randomised controlled trial of probiotics using electronic health records
inferred← citeshttps://doi.org/10.1038/s41598-019-54180-4openalex-snapshot
A framework for identification of on- and off-target transcriptional responses to drug treatment
inferred← citeshttps://doi.org/10.1038/s41598-021-82840-xopenalex-snapshot
Predictive modeling of clinical trial terminations using feature engineering and embedding learning
inferred← citeshttps://doi.org/10.1038/s41598-022-08454-zopenalex-snapshot
A knowledge graph of clinical trials ($$\mathop {\mathtt {CTKG}}\limits$$)
inferred← citeshttps://doi.org/10.1038/s41746-021-00452-1openalex-snapshot
Exploring the feasibility of using real-world data from a large clinical data research network to simulate clinical trials of Alzheimer’s disease
inferred← citeshttps://doi.org/10.1038/s41746-021-00473-wopenalex-snapshot
Empowering clinical research in a decentralized world
inferred← citeshttps://doi.org/10.1038/s43018-020-0074-yopenalex-snapshot
The impact of the COVID-19 pandemic on cancer care
inferred← citeshttps://doi.org/10.1039/d2me00142jopenalex-snapshot
3D-printed, configurable, paper-based, and autonomous multi-organ-on-paper platforms
inferred← citeshttps://doi.org/10.1053/j.semvascsurg.2026.02.002openalex-snapshot
CREST-2: Early reflections on the primary results
inferred← citeshttps://doi.org/10.1056/evidoa2200195openalex-snapshot
Meta-Analysis of Candidate Surrogate End Points in Advanced Prostate Cancer
inferred← citeshttps://doi.org/10.1080/03007995.2022.2103960openalex-snapshot
Trend of drug clinical trials in mainland China from 2009 to 2020
inferred← citeshttps://doi.org/10.1080/0886022x.2026.2629639openalex-snapshot
Landscape of diabetic kidney disease drug clinical trials in China (2013–2023): global implications for innovation and policy
inferred← citeshttps://doi.org/10.1080/08989621.2022.2078711openalex-snapshot
Should informed consent and information related to patient recruitment in clinical trials be available to the reader of scientific articles? A case study in dentistry
inferred← citeshttps://doi.org/10.1080/09540261.2025.2564155openalex-snapshot
Early intervention for psychiatry itself: the invisible hands for future psychiatry
inferred← citeshttps://doi.org/10.1080/10428194.2024.2416565openalex-snapshot
Analyzing determinants of premature trial discontinuation in leukemia clinical trials
inferred← citeshttps://doi.org/10.1080/10543406.2025.2547593openalex-snapshot
Mitigating propensity score model misspecification with multiply robust weights when leveraging external data
inferred← citeshttps://doi.org/10.1080/14737175.2023.2215429openalex-snapshot
Clinical trials for neuroregenerative therapies for spinal cord injury: what have we learnt so far?
inferred← citeshttps://doi.org/10.1080/14740338.2018.1546842openalex-snapshot
Should real-world evidence be incorporated into regulatory approvals?
inferred← citeshttps://doi.org/10.1080/14787210.2019.1550357openalex-snapshot
Teixobactin: a novel anti-infective agent
inferred← citeshttps://doi.org/10.1080/16549716.2018.1431362openalex-snapshot
Setting up a clinical trial for a novel disease: a case study of the Doxycycline for the Treatment of Nodding Syndrome Trial – challenges, enablers and lessons learned
inferred← citeshttps://doi.org/10.1080/17425247.2016.1244187openalex-snapshot
Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures
inferred← citeshttps://doi.org/10.1080/17460441.2020.1757644openalex-snapshot
Porcine cancer models: potential tools to enhance cancer drug trials
inferred← citeshttps://doi.org/10.1080/19466315.2023.2292815openalex-snapshot
Predicting Probability of Success for Phase III Trials via Propensity-Score-Based External Data Borrowing
inferred← citeshttps://doi.org/10.1080/19466315.2026.2621850openalex-snapshot
Phase 2 Design Considerations from a Program Perspective
inferred← citeshttps://doi.org/10.1080/87559129.2025.2597422openalex-snapshot
The Chemopreventive and Antitumor Potential of Cranberry ( Vaccinium Macrocarpon Aiton) in Gastrointestinal Cancers: A Review of Molecular Mechanisms, Preclinical Evidence, and Commercial Perspectives
inferred← citeshttps://doi.org/10.1089/aipo.2024.0027openalex-snapshot
The Most Disruptive Near-Term Use of AI in Cancer Care: Patient Empowerment Through Software Agents
inferred← citeshttps://doi.org/10.1093/bib/bbz165openalex-snapshot
Predicting drug-induced hepatotoxicity based on biological feature maps and diverse classification strategies
inferred← citeshttps://doi.org/10.1093/bioinformatics/btac192openalex-snapshot
Interpretable-ADMET: a web service for ADMET prediction and optimization based on deep neural representation
inferred← citeshttps://doi.org/10.1093/cid/ciaa246openalex-snapshot
Geographic Shifts in Antibacterial Drug Clinical Trial Enrollment: Implications for Generalizability
inferred← citeshttps://doi.org/10.1093/cid/ciaa930openalex-snapshot
Investigator-initiated Randomized Controlled Trials in Infectious Diseases: Better Value for Money for Registration Trials of New Antimicrobials
inferred← citeshttps://doi.org/10.1093/cid/cix726openalex-snapshot
Cost Drivers of a Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial
inferred← citeshttps://doi.org/10.1093/cvr/cvab075openalex-snapshot
Alternative strategies in cardiac preclinical research and new clinical trial formats
inferred← citeshttps://doi.org/10.1093/ecco-jcc/jjz214openalex-snapshot
Phase I, II and III Trials in Inflammatory Bowel Diseases: A Practical Guide for the Non-specialist
inferred← citeshttps://doi.org/10.1093/eurheartj/ehy235openalex-snapshot
The learning health system: trial design and participant consent in comparative effectiveness research
inferred← citeshttps://doi.org/10.1093/humrep/dex282openalex-snapshot
Pharmaceutical industry contribution to research is essential but full transparency and guidelines are required
showing the first 200 of 393
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.